Folder #: 0000000004 David Maseko

## CLINICAL NOTES

| Date | Weight | Progress Notes | Return Date | Signature |
|---|---|---|---|---|
| 18/10/16 | 63 | Positive Screened: 01/10/16 | | |
| | | GXP specimen collected: 01/10/16.GXP positive - Difficult to locate lab results from NHLS | | |
| | | | | |
| | | Arrrived at clinic 18/10/16 | | |
| | | Started treatment: 3 RHZE/day/2weeks (14 days) | | |
| | | Baseline smear collected: 18/10/16 | 01/11/16 | |
| | | | | |
| 01/11/16 | 63,5 | Baseline Smear results P+++ | | |
| | | Progressing well, no side effects reported. Eating more frequently | | |
| | | RHZE continued 2 weeks (14 days) | 15/11/2016 | |
| | | | | |
| 15/11/16 | 67 | No complaints raised. Gradual weight gain marked. No adverse events reported. | | |
| | | RHZE continued 3 weeks (21 days) | 06/12/16 | |
| | | | | |
| 06/12/16 | 68 | Sputum collected for conversion | | |
| | | RHZE continued 1 weeks (7 days) | 13/12/16 | |
| | | | | |
| 13/12/16 | 68 | Sputum results P+ | | |
| | | Checked for treatment compliance and reassessed patient clinically. | | |
| | | Collect sputum specimen for LPA test | | |
| | | Increased intensive phase treatment for another 3 weeks (21 days) | 03/01/17 | |
| | | | | |
| | | | | |
| | | | | |
| 03/01/17 | 68 | LPA Result: Negative | | |
| | | Sputum collected for 3rd month conversion | | |
| | | RHZE continued for 3 days | 06/01/17 | |
| | | | | |
| | | | | |
| 13/01/17 | | Patient was traced and could not be found at the given address | | |
| | | | | |
| 23/01/17 | | 2nd tracing attempt, patient not found | | |
| | | | | |
| 03/03/17 | | Patient not found - LTF | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| Date | Weight | Progress Notes | Return Date | Signature |
| --- | --- | --- | --- | --- |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |